Enterome
Private Company
Total funding raised: $135.2M
Overview
Enterome is a pioneering French biotech translating microbiome science into innovative cancer immunotherapies. Its proprietary Mimicry platform screens a vast database of gut microbiome proteins to discover OncoMimics™, off-the-shelf peptide therapies designed to overcome immune tolerance. The company has advanced three Phase 2 candidates targeting glioblastoma, lymphomas, adrenal tumors, and colorectal cancer, demonstrating promising early efficacy and safety. With strong leadership and significant capital raised, Enterome is positioned as a key player in the next wave of immuno-oncology.
Technology Platform
Proprietary Mimicry platform that uses biocomputational tools to mine a database of 20+ million gut microbiome proteins to identify OncoMimics™ peptides. These peptides mimic tumor antigens and reactivate pre-existing memory T cells to attack cancer.
Funding History
4Opportunities
Risk Factors
Competitive Landscape
Enterome competes in the crowded cancer immunotherapy space against dominant checkpoint inhibitors, targeted therapies, and cell therapies. Its primary differentiation is its novel microbiome-derived, off-the-shelf peptide approach, which contrasts with personalized cell therapies. Competitors include other biotechs developing cancer vaccines and peptide-based immunotherapies, though few leverage the gut microbiome as a drug discovery source.